Drugs / HBV vaccine
HBV vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01878565 | Jun 2013 → Dec 2014 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03332329 | Dec 2015 → Dec 2018 | chronic hepatitis B virus infection | Qin Ning | Unknown | No outcome recorded |
| Phase 4 | NCT02584543 | Oct 2015 → Aug 2016 | hepatitis B virus infection, hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00476411 | Dec 2006 → Jun 2008 | hepatitis B virus infection | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05380388 Background | Jan → Dec 2027 expected | Plasmodium vivax malaria | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00886964 Comparator | Apr 2009 → May 2010 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 3 | NCT01884415 Comparator | Sep 2012 → Dec 2017 | cirrhosis of liver, hepatitis B virus infection | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
Press releases naming this drug 9 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV vaccine | “To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab” NCT00886964 ↗6“and finally were injected 20 μg of HBV vaccine subcutaneously at day 6” NCT01878565 ↗ |
| Known as | Hepatitis B vaccine | “The concomitant group (n =300) received Hepatitis B vaccine concomitantly with Hepatitis E vaccine at day 1 and months 1 and 6;” NCT02584543 ↗ |
| Known as | Recombinant Hepatitis B Vaccine | “Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine” NCT02584543 ↗ |
| Action | Activate | “finally HBV vaccine is used to priming APC to induce HBV-specific immune responses” NCT01878565 ↗ |
| Modality | Vaccine | “HBV vaccine” NCT00476411 ↗ |
| Route | Subcutaneous | “20 μg of HBV vaccine subcutaneously” NCT01878565 ↗ |